EpimAb Biotherapeutics
EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing bispecific and multispecific antibody therapeutics for oncology and autoimmune diseases using its proprietary FIT-Ig® platform, generating revenue through licensing and milestone-based partnerships with global pharmaceutical companies.
- Company typePrivate
- Founded2015
- HeadquartersShanghai, China
- Headcount51–100
- GTM typeB2B
- OfferingServices
What EpimAb Biotherapeutics does
EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Shanghai, China, with operating subsidiaries in Suzhou and Beijing and a Cayman Islands parent entity. The company develops multispecific antibody therapeutics for oncology and autoimmune diseases, anchored by its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) bispecific platform, complemented by the MAT-Fab platform and the newly disclosed ProTCE (Prodrug T-Cell Engager) platform introduced at AACR 2026. FIT-Ig® combines two parental antibodies into a single tetravalent molecule with mAb-like manufacturability, solubility, and tissue penetration, avoiding Fc mutations, scFvs, linkers, and peptide connectors. Its clinical pipeline comprises three assets — EMB-01 (EGFR/cMET, Phase II), EMB-06 (BCMA/CD3, Phase I in autoimmune indications), and EMB-07 (ROR1/CD3, FDA IND cleared in 2025) — alongside more than ten preclinical candidates spanning tumor targeting, dual checkpoint regulators, and immune cell engagers.
The company makes money primarily through licensing and partnership agreements: it out-licenses the FIT-Ig® platform and pipeline assets to global pharmaceutical and biotechnology partners in exchange for upfront payments, development/regulatory/commercial milestones, and royalties. Named licensees and collaborators include Almirall (Spain, FIT-Ig® bispecifics, with the first CTA filed in February 2026), Juri Biosciences (worldwide license for a KLK2-directed T-cell engager in metastatic prostate cancer, May 2025), Vignette Bio (undisclosed targets, 2024), and Candid (sponsor of EMB-06 Phase I trials in SLE, gMG, and Thyroid Eye Disease, 2024). Go-to-market is conducted through dedicated business development outreach ([email protected]), participation in international partnering conferences, and scientific presentations. To date, EpimAb has raised approximately $219M+ across Seed, Series A ($25M, 2017), Series B ($74M, 2019), Series C ($120M, 2021), and 2022 convertible notes, sustaining a 51–100-person organization advancing assets through global clinical trials in the US, China, and Australia.
EpimAb Biotherapeutics firmographics
Firmographics- Name
- EpimAb Biotherapeutics
- Legal name
- EpimAb Biotherapeutics, Inc
- Website
- https://epimab.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing bispecific and multispecific antibody therapeutics for oncology and autoimmune diseases using its proprietary FIT-Ig® platform, generating revenue through licensing and milestone-based partnerships with global pharmaceutical companies.
- Ownership category
- akta.pro rank
EpimAb Biotherapeutics industry classification
Industry- Product category
- Bispecific Antibody Therapeutics
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where EpimAb Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
EpimAb Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and partnership agreements: EpimAb generates revenue through licensing its proprietary FIT-Ig® technology platform and pipeline assets to pharmaceutical partners. This includes upfront payments, milestone payments tied to development, regulatory, and commercial achievements, as well as royalties on net sales of licensed products.
- Research collaborations: The company enters into research collaborations with partners like Candid, generating revenue through research funding and potential future licensing rights.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
EpimAb Biotherapeutics product offering
Product offeringCore offering
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab platforms. The company generates revenue by licensing its bispecific antibody technology and pipeline assets to global pharmaceutical partners. Its pipeline includes three clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than ten preclinical candidates across oncology and autoimmune disease indications.
Product overview
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics. The company's core proprietary technology platforms are FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab), which generate bispecific molecules with antibody-like properties. The pipeline consists of 3 clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than 10 preclinical candidates targeting strategic oncology areas including tumor targeting, dual checkpoint regulators, and immune cell engagers. The company also announced a novel ProTCE (Prodrug T-Cell Engager) platform in 2026.
Differentiator
Problem solved
Functional benefit
Brands
- FIT-Ig: Fabs-In-Tandem Immunoglobulin - proprietary bispecific antibody technology platform
- MAT-Fab
Products and services
- FIT-Ig® (Fabs-In-Tandem Immunoglobulin) Proprietary bispecific antibody platform that combines two parental antibodies into one molecule by rearranging DNA sequences into three genetic constructs co-expressed in mammalian cells; produces tetravalent bispecific antibodies with antibody-like manufacturability and solubility, licensed to pharmaceutical partners.
- MAT-Fab (Monovalent Asymmetric Tandem Fab) In-house bispecific platform technology used alongside FIT-Ig® to generate multispecific antibodies for therapeutic development and licensing.
- EMB-01 (EGFR/cMET) Clinical-stage bispecific antibody targeting EGFR and cMET for advanced or metastatic gastrointestinal cancers including colorectal cancer, hepatocellular carcinoma, gastric cancer, and biliary tract cancer.
- EMB-06 (BCMA/CD3) Clinical-stage T-cell engager targeting BCMA and CD3 for B-cell related autoimmune diseases including systemic lupus erythematosus (SLE) and generalized myasthenia gravis (gMG).
- EMB-07 (ROR1/CD3) Clinical-stage T-cell engager targeting ROR1 and CD3 for solid tumors and relapsed or refractory lymphoma including DLBCL.
- ProTCE Platform (Prodrug T-Cell Engager) Novel Prodrug T-Cell Engager platform enabling tumor-restricted activity of T-cell engagers, expanding EpimAb's multispecific antibody capabilities for oncology applications.
Companies that use EpimAb Biotherapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
EpimAb Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
EpimAb Biotherapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and key.
- Juri BiosciencescoreJuri Biosciences, a TCG Labs Soleil Portfolio Company, entered into a worldwide licensing agreement with EpimAb for KLK2-Directed T-Cell Engager in metastatic prostate cancer in May 2025. This represents a significant validation of EpimAb's T-cell engager technology and expands the company's pipeline into a new therapeutic area.
- Vignette BiokeyVignette Bio entered into a license agreement with EpimAb in 2024 for undisclosed targets, expanding the global reach of EpimAb's bispecific antibody technology.
- CandidkeyEpimAb established a research collaboration with Candid in 2024 for autoimmune disease programs. Candid is sponsoring ongoing Phase I trials in SLE (Systemic Lupus Erythematosus) and gMG (generalized Myasthenia Gravis), as well as TED (Thyroid Eye Disease).
- AlmirallcoreAlmirall, a Spain-based dermatology-focused pharmaceutical company, entered into an option and evaluation agreement with EpimAb in 2023. Almirall filed the first CTA (Clinical Trial Application) for a FIT-Ig® bispecific antibody in February 2026, marking a significant milestone for the partnership and demonstrating clinical translation of EpimAb's technology platform.
- EpimAb Holdings (Cayman)coreParent company incorporated in Cayman Islands in November 2021 (EpimAb Holdings). Original group founded in Cayman Islands in 2015.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
EpimAb Biotherapeutics competitors and assessment
Company assessmentDirect peers
- Genmab: Genmab develops the DuoBody® bispecific antibody platform, the global commercial leader in bispecific antibody technology — the closest functional analog to EpimAb's FIT-Ig® platform. Both companies commercialize bispecific technology through licensing and co-development with major pharma.
- Zymeworks: Zymeworks operates the Azymetric™ and EFFECT™ platforms for bispecific and multispecific antibodies, with a similar business model of partnering pipeline and platform assets with large pharma — directly comparable in technology category and licensing-driven GTM.
- Xencor: Xencor's XmAb® bispecific and multispecific antibody platform and partnered pipeline (multiple pharma licensees) makes it a closely comparable platform-and-partnering biotech operating in the same technology category as EpimAb.
- MacroGenics: MacroGenics develops DART® and TRIDENT® bispecific/multispecific antibody platforms with clinical assets across oncology, employing a similar platform-plus-partnering model focused on immuno-oncology — directly comparable in therapeutic focus and modality.
- Akeso: Akeso is a Chinese clinical-stage biotech known for its in-house bispecific antibody pipeline (e.g., PD-1/VEGF, PD-1/CTLA-4) that is the closest geographic and strategic analog to EpimAb. Both are China-headquartered bispecific innovators advancing oncology assets through partnerships.
Broad incumbents
- Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company with a broader biologics portfolio including bispecifics, antibodies, and ADCs. Comparable as a Chinese biologics innovator with global pharma partnerships, though it is more diversified beyond pure bispecifics.
- Junshi Biosciences: Junshi is a Chinese clinical-stage biopharmaceutical developer with a broad oncology and immunology pipeline including bispecifics. Comparable as a China-based biologics innovator pursuing partnership strategies with major pharma for late-stage commercialization.
- BeiGene: BeiGene is a major Chinese-founded biotech with a global commercial footprint and broad oncology pipeline. Operates in the same China biotech ecosystem and pursues similar biologic and immuno-oncology programs, though at a meaningfully larger scale than EpimAb.
- Eli Lilly: Lilly has active bispecific antibody programs (e.g., in oncology and immunology, with assets developed via acquisition of Loxo and other platforms) — relevant as a large pharma incumbent in the bispecific space that may compete for partner deals or look to license from platform companies like EpimAb.
Others
- Roche: Roche is a global pharma leader with the bispecific antibody Hemlibra (emicizumab) and a deep internal bispecific pipeline. Relevant as the dominant incumbent that EpimAb partners with or competes against for bispecific technologies and pipeline assets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
EpimAb Biotherapeutics social profiles
Digital presenceEpimAb Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
EpimAb Biotherapeutics leadership team
Management profileNumber of profiles
Profiles5 records
EpimAb Biotherapeutics subsidiaries and ownership
Company hierarchySubsidiaries3 records
EpimAb Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EpimAb Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EpimAb Biotherapeutics
What does EpimAb Biotherapeutics do?
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab platforms. The company generates revenue by licensing its bispecific antibody technology and pipeline assets to global pharmaceutical partners. Its pipeline includes three clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than ten preclinical candidates across oncology and autoimmune disease indications.
Is EpimAb Biotherapeutics a public or private company?
EpimAb Biotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was EpimAb Biotherapeutics founded?
EpimAb Biotherapeutics was founded in 2015. It employs 51 to 100 people.
Where is EpimAb Biotherapeutics based?
EpimAb Biotherapeutics is headquartered in Shanghai, China, in the Asia region.
How does EpimAb Biotherapeutics make money?
Two revenue lines are on record. Licensing and partnership agreements are the primary driver. The others are research collaborations.
Who are EpimAb Biotherapeutics's main competitors?
Direct peers on record are Genmab, Zymeworks, Xencor, MacroGenics and Akeso. Broad incumbents are Innovent Biologics, Junshi Biosciences, BeiGene and Eli Lilly. Roche is listed as an others.
Does EpimAb Biotherapeutics have an API?
No public API is recorded for EpimAb Biotherapeutics.
What industry is EpimAb Biotherapeutics in?
EpimAb Biotherapeutics's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its SIC code is 2836.